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To apply M-CHARTS for quantitative measurements of metamorphopsia in eyes with acute
branch retinal vein occlusion (BRVO) and to elucidate the pathomorphology that causes
metamorphopsia.
Methods
This prospective study consisted of 42 consecutive patients (42 eyes) with acute BRVO.
Both at baseline and one month after treatment with ranibizumab, metamorphopsia was
measured with M-CHARTS, and the retinal morphological changes were examined with
optical coherence tomography.
Results
At baseline, metamorphopsia was detected in the vertical and/or horizontal directions in 29
(69.0%) eyes; the mean vertical and horizontal scores were 0.59 ± 0.57 and 0.52 ± 0.67,
respectively. The maximum inner retinal thickness showed no association with the M-
CHARTS score, but the M-CHARTS score was correlated with the total foveal thickness (r =
0.43, p = 0.004), the height of serous retinal detachment (r = 0.31, p = 0.047), and the maxi-
mum outer retinal thickness (r = 0.36, p = 0.020). One month after treatment, both the inner
and outer retinal thickness substantially decreased. However, metamorphopsia persisted in
26 (89.7%) of 29 eyes. The posttreatment M-CHARTS score was not correlated with any
posttreatment morphological parameters. However, the posttreatment M-CHARTS score
was weakly correlated with the baseline total foveal thickness (r = 0.35. p = 0.024) and
closely correlated with the baseline M-CHARTS score (r = 0.78, p < 0.001).
Conclusions
Metamorphopsia associated with acute BRVO was quantified using M-CHARTS. Initial
microstructural changes in the outer retina from acute BRVOmay primarily account for the
metamorphopsia.
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Introduction
Macular edema (ME) is one of the main causes of the decrease in visual acuity (VA) associated
with acute branch retinal vein occlusion (BRVO) [1]. The visual prognosis of BRVO has been
substantially improved since the introduction of anti-vascular endothelial growth factor agents
[2, 3]. However, some patients suffer from a decreased quality of vision due to symptomatic
metamorphopsia, even after the complete reduction of ME. Recent advancements in ophthal-
mic instruments have improved our understanding of the pathophysiology of retinal complica-
tions associated with BRVO and their correlations with subjective symptoms [4]. However, our
understanding of metamorphopsia caused by BRVO remains limited due to the lack of meth-
odologies to quantify the degree of metamorphopsia [5–10]. In addition, BRVO, which is
caused by a circulatory disturbance within the inner retina, shows various features, such as reti-
nal swelling, retinal cystoid spaces, retinal hemorrhage, non-perfusion area, and serous retinal
detachment, and these morphological changes extend from the inner retina to the subretinal
spaces [1]. Such complexity in the pathologic features makes it difficult to elucidate the patho-
genesis of metamorphopsia associated with acute BRVO.
M-CHARTS, developed by Matsumoto et al.[11], allows us to quantitatively evaluate the
degree of metamorphopsia. M-CHARTS consists of a series of 19 dotted line tests in which the
intervals of each dot range from 0.2° to 2.0°. In patients with metamorphopsia, a dotted line
with a small interval is often recognized as distorted. As the dot interval increases, the distor-
tion of the line decreases. With M-CHARTS, metamorphopsia is quantified as the minimum
interval at which no visual distortion is present. To date, quantitative evaluations with
M-CHARTS have been applied in epiretinal membrane [11–21], rhegmatogenous retinal
detachment [22], age-related macular degeneration [23, 24], diabetic macular edema [25], mac-
ular hole [26, 27], and central serous chorioretinopathy [28, 29]. Based on the use of
M-CHARTS for epiretinal membrane, it has been reported that the severity of metamorphop-
sia is related to the thickness of the inner nuclear layer measured with optical coherence
tomography (OCT) [15, 21, 30] or foveal microfolds visualized using adaptive optics-scanning
laser ophthalmoscopy [13].
However, few investigators have quantitatively evaluated metamorphopsia associated with
BRVO; using M-CHARTS, Nakagawa et al.[6], studied metamorphopsia in 12 eyes with
BRVO, and Achiron et al.[5] detected metamorphopsia in 4 eyes with retinal vein occlusion.
To the best of our knowledge, no previous reports have described the retinal pathomorphology
that is involved in the metamorphopsia associated with BRVO. Therefore, the purposes of the
current study were (1) to perform quantitative measurements of metamorphopsia with
M-CHARTS in eyes with acute BRVO in order to determine the prevalence and severity of
metamorphopsia and (2) to compare the M-CHARTS score with the retinal morphology mea-
sured using OCT in order to elucidate the pathomorphology that causes metamorphopsia.
Patients and Methods
This study was approved by the Ethics Committee at Kagawa University Faculty of Medicine
and conducted in accordance with the tenets of the Declaration of Helsinki. Written informed
consent was obtained from each subject before any study procedures or examinations were
performed.
Patients
This prospective study consisted of 42 consecutive patients (42 eyes) with ME associated with
acute BRVO who were examined and treated at the Department of Ophthalmology of Kagawa
University Hospital between September 2014 and September 2015.
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The inclusion criteria of this study were (1) symptomatic BRVO, in which retinal hemor-
rhage and retinal edema involved the macula, (2) foveal thickness of greater than 250 μm at the
initial visit as measured by OCT, and (3) a duration of symptoms prior to the initial examina-
tion of less than 3 months. The diagnosis of BRVO was based on fundus examinations and
fluorescein angiography findings determined by two retina specialists (KM, AT). Eyes with
central retinal vein occlusion or hemi-central retinal vein occlusion were not included in the
current study. Eyes with co-existing ocular disease (i.e., age-related macular degeneration, reti-
nitis pigmentosa, diabetic retinopathy, retinal macroaneurysm, or senile cataract that resulted
in poor image quality), and eyes that had any history of interventions for ME before inclusion
in the study were excluded.
Schedule of evaluation
At the initial visit, the medical history was obtained from each patient. Each patient underwent
a comprehensive ophthalmologic examination, including measurement of the best-corrected
VA using the Landolt chart and the degree of metamorphopsia by M-CHARTS (Inami, Tokyo,
Japan), determination of intraocular pressure, indirect ophthalmoscopy, slit-lamp biomicro-
scopy with a noncontact lens, OCT examinations (Spectralis HRA+OCT; Heidelberg Engineer-
ing, Heidelberg, Germany), and fluorescein angiography (Optos 200Tx imaging system, Optos
PLC, Dunfermline, United Kingdom).
Each patient was treated with an intravitreal injection of ranibizumab (Lucentis; Novartis
Pharma, Tokyo, Japan) for ME. In order to evaluate the retinal morphology and visual function
during the recovery from ME, each patient was scheduled for reevaluation of the retinal mor-
phology and visual function one month after the initial injection. One month after the treat-
ment, all eyes showed a marked reduction of ME and frequently achieved an improvement of
visual symptoms and VA. Each patient underwent a complete ophthalmologic examination,
including measurement of the VA and M-CHARTS score, slit-lamp biomicroscopy, indirect
fundus ophthalmoscopy, and OCT examination. Fluorescein angiography was performed as
necessary.
Each patient was examined at our clinic every month. Thereafter, most eyes showed the
indeterminate recurrence of ME. Additional injections were performed when ME and/or
serous retinal detachment was evident at the fovea on OCT examination.
Metamorphopsia evaluation
M-CHARTS is commercially available to quantify the degree of metamorphopsia. The princi-
pal of M-CHARTS has been described in detail previously (Fig 1) [11]. In brief, M-CHARTS is
composed of a series of 19 dotted line tests. In each chart, the intervals of each dot range from
0.2° to 2.0°. A fixation point is printed in the center of each line, measuring 0.3° of the visual
angle. First, an examiner presents a chart with a solid line at a distance of 30 cm under the cor-
rection of the refraction, followed by charts with dotted lines of incrementally increasing spac-
ing. For each chart, the patient is asked to state whether the presented line is distorted or not.
As the visual angle increases, the degree of metamorphopsia decreases. When the patient rec-
ognizes the presented line as being straight, the visual angle of that line is taken as the degree of
metamorphopsia. M-CHARTS were presented to the patient in a vertical direction and then in
a horizontal direction. The vertical and horizontal scores were measured, and the higher score
was used as the M-CHARTS score for the eye.
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Measurement of retinal structural changes with optical coherence
tomography
Morphologic evaluations and quantitative measurements of ME associated with BRVO were
performed by OCT. The entire macular area was examined with sequential OCT sectioning to
detect any serous retinal detachment or cystoid spaces. Quantitative measurements were per-
formed using a vertical section acquired through the foveal center because the BRVO-affected
retina was mainly located on either the upper hemisphere or the lower hemisphere of the ret-
ina. In the current study, the thickness of the inner retina was defined as the vertical distance
between the vitreoretinal interface and the outer surface of the inner nuclear layer. The thick-
ness of the outer retina was defined as the vertical distance between the outer surface of the
inner nuclear layer and the inner surface of the retinal pigment epithelium. The total retinal
thickness was defined as the distance between the vitreoretinal interface and the inner surface
of the retinal pigment epithelium.
On the vertical section through the foveal center, the inner, outer, and total retinal thickness
were measured at 1 mm, 2 mm, and 3 mm from the foveal center on the affected retinal side,
respectively (Fig 2). The maximum thickness of the inner, outer, or total retina was defined as
the maximum value among the three measurements (Fig 2). The thickness of the serous retinal
detachment was measured manually at the largest point, which was frequently at the fovea
[31]. These measurements were performed at baseline and one month after the initial treat-
ment by one grader (KM) in a masked fashion.
Fig 1. Quantitative measurement of metamorphopsia using M-CHARTS in eyes with acute branch retinal vein occlusion. First, a chart with a solid
line was presented at a distance of 30 cm. Thereafter, charts with dotted lines with incrementally larger spacing were presented. When the patient recognizes
the presented line as being straight, the visual angle of that line is taken as the metamorphopsia degree. The vertical and horizontal score was measured,
and the higher score was used as the M-CHARTS score. In this eye, the vertical (A) and horizontal (B) metamorphopsia were 0.5 and 0.4. The M-CHARTS
score of this eye is 0.5.
doi:10.1371/journal.pone.0153817.g001
Metamorphopsia in Branch Retinal Vein Occlusion
PLOS ONE | DOI:10.1371/journal.pone.0153817 April 28, 2016 4 / 14
Statistical analysis
Statistical analysis was performed using SPSS, version 21.0.0 (IBM Japan, Tokyo, Japan). All
values are presented as the means ± standard deviation. The best-corrected VA was converted
to a logarithm of the minimum angle of resolution (logMAR) equivalent for statistical analysis.
The M-CHARTS score was considered to be changed when the change in score was greater
than 0.1 [11]. Comparisons between baseline and posttreatment values were performed using
the paired t-test. Bivariate relationships were analyzed using the Pearson’s correlation coeffi-
cient to evaluate the correlation between each measurement value and the M-CHARTS score.
A value of p< 0.05 was considered statistically significant.
Results
Table 1 shows the baseline measurements of all patients eligible in this study. At baseline, all
eyes showed visual disturbance associated with acute BRVO; the mean VA was 0.33 ± 0.31,
and the mean total foveal thickness was 467.2 ± 191.5 μm. The maximum inner, outer, and
total retinal thickness was 312.6 ± 90.4 μm, 294.5 ± 114.3 μm, and 588.3 ± 163.9 μm, respec-
tively. Of 42 eyes, 21 (50.0%) showed serous retinal detachment at the fovea.
Metamorphopsia was quantified using M-CHARTS. Of 42 eyes, no metamorphopsia was
detected in 13 (31.0%) eyes. Metamorphopsia was detected in the vertical and/or horizontal
directions in 29 (69.0%) eyes. The mean vertical and horizontal scores were 0.59 ± 0.57 and
0.52 ± 0.67, respectively (Table 2). The vertical score was slightly greater than the horizontal
score, although the difference was not significant (p = 0.070).
The higher score of the vertical and horizontal scores was used as the M-CHARTS score.
Table 3 shows the association of the baseline M-CHARTS score and the baseline morphologi-
cal parameters with OCT. While the VA showed no association with the M-CHARTS score,
Fig 2. Quantitative measurements of retinal morphological changes associated with acute branch retinal vein occlusion with optical coherence
tomography.On the vertical section through the foveal center, the inner (yellow arrows), outer (blue arrows), and total (red arrows) retinal thickness was
measured at 1 mm, 2 mm, and 3 mm from the center of the fovea toward the affected side of the retina, respectively. The maximum thickness of the inner,
outer, or total retina was determined as the largest among the three measurements.
doi:10.1371/journal.pone.0153817.g002
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the total foveal thickness was associated with the M-CHARTS score (r = 0.43, p = 0.004). The
M-CHARTS score had no association with the maximum inner retinal thickness (r = 0.10,
p = 0.527), but it was correlated with the thickness of the serous retinal detachment (r = 0.31,
p = 0.047) and with the maximum outer retinal thickness (r = 0.36, p = 0.020; Fig 3). Metamor-
phopsia seemed to be mainly associated with the morphological changes of the outer aspect of
the retina.
One month after the initial treatment, most eyes showed a marked reduction of ME
(Table 4). Both the inner and outer retinal thickness were significantly decreased, not only at
the fovea, but also at the parafoveal area (p< 0.001). The mean VA was improved from
0.33 ± 0.31 to 0.23 ± 0.29 (p< 0.001). However, metamorphopsia persisted in most eyes,
Table 2. Baseline Score of Metamorphopsia Measured with M-CHARTS.
Vertical score 0.59 ± 0.57
Horizontal score 0.52 ± 0.67
Higher score 0.68 ± 0.67
Higher score is determined from the vertical and horizontal scores.
doi:10.1371/journal.pone.0153817.t002
Table 1. Baseline Characteristics of Eyes with Acute Branch Retinal Vein Occlusion.
Age, years 69.0 ± 11.4
Gender, women/men 20/22
Duration of symptom until examination, weeks 5.5 ± 5.2
Visual acuity, logMAR 0.33 ± 0.31
Total foveal thickness, μm 467.2 ± 191.5
Thickness of serous retinal detachment, μm 149.0 ± 95.7
Maximum of total retinal thickness, μm 588.3 ± 163.9
Maximum of inner retinal thickness, μm 312.6 ± 90.4
Maximum of outer retinal thickness, μm 294.5 ±114.3
All values are presented as the mean ± standard deviation.
logMAR, logarithm of the minimum angle of resolution.
doi:10.1371/journal.pone.0153817.t001
Table 3. Association between Baseline M-CHARTS Score and Baseline Pathomorphological Parame-
ters of Eyes with Acute Branch Retinal Vein Occlusion.
r p-value
Age 0.15 0.342
Visual acuity (logMAR) 0.19 0.219
Total foveal thickness 0.43 0.004
Thickness of serous retinal detachment 0.31 0.047
Maximum of total retinal thickness 0.25 0.116
Maximum of inner retinal thickness 0.10 0.527
Maximum of outer retinal thickness 0.36 0.020
logMAR, logarithm of the minimum angle of resolution.
M-CHARTS Score is the higher score of the vertical and horizontal scores of M-CHARTS.
doi:10.1371/journal.pone.0153817.t003
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although there was some improvement (Fig 4). Of 29 eyes that had metamorphopsia at base-
line, metamorphopsia was completely eliminated in only three (10.3%) eyes, and it persisted in
26 (89.7%) eyes (Fig 5). In addition, two eyes developed metamorphopsia after treatment. Of
42 eyes, the M-CHARTS score was decreased in 13 (31.0%) eyes and increased in 8 (19.0%)
eyes after the treatment. The change in the M-CHARTS score after the treatment was signifi-
cantly correlated with the baseline score (r = -0.48, p = 0.001). The mean M-CHARTS score
was decreased with treatment, but the improvement was not significant (p = 0.050).
Table 5 shows the association between the posttreatment M-CHARTS score and the other
posttreatment measurement values. Of 42 patients, 28 eyes had metamorphopsia after the
treatment. No posttreatment factors had an association with the posttreatment M-CHARTS
Fig 3. Association between the M-CHARTS score and the total foveal thickness (A) and the maximum outer retinal thickness (B) in the macular
area affected by acute branch retinal vein occlusion.
doi:10.1371/journal.pone.0153817.g003
Table 4. Measurement Values Associated with Acute Branch Retinal Vein Occlusion at Baseline and One Month after Initial Treatment with
Ranibizumab.
Baseline One Month p-value
Visual acuity, logMAR 0.33 ± 0.31 0.23 ± 0.29 < 0.001
Total foveal thickness, μm 467.2 ± 191.5 287.8 ± 115.8 < 0.001
Thickness of serous retinal detachment, μm 149.0 ± 95.7 55.0 ± 39.8 0.069
Maximum of total retinal thickness, μm 588.3 ± 163.9 437.3 ± 87.4 < 0.001
Maximum of inner retinal thickness, μm 312.6 ± 90.4 244.9 ± 54.8 < 0.001
Maximum of outer retinal thickness, μm 294.5 ±114.3 204.1 ± 60.5 < 0.001
M-CHARTS
Vertical score 0.59 ± 0.57 0.50 ± 0.51 0.020
Horizontal score 0.52 ± 0.67 0.43 ± 0.54 0.150
Higher score 0.68 ± 0.67 0.57 ± 0.60 0.050
logMAR, logarithm of the minimum angle of resolution.
M-CHARTS Score is the higher score of the vertical and horizontal scores of M-CHARTS.
doi:10.1371/journal.pone.0153817.t004
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score. Table 6 shows the association between the posttreatment M-CHARTS score and the
baseline measurement values. The posttreatment M-CHARTS score was weakly correlated
with the total foveal thickness (r = 0.35, p< 0.024) and closely correlated with the M-CHARTS
at baseline (r = 0.78, p< 0.001).
Fig 4. Correlations between the baseline and the posttreatment total foveal thickness (A), maximum outer retinal thickness (B), visual acuity (C),
and M-CHARTS score (D) in eyes with acute branch retinal vein occlusion that were treated with an intravitreal injection of ranibizumab.One month
after the initial treatment, the maximum outer retinal thickness and total foveal thickness and was significantly decreased (both p < 0.001). The visual acuity in
logMAR was also significantly improved (p < 0.001). The improvement in the meanM-CHARTS score was not significant (p = 0.050), and 28 eyes still had
metamorphopsia.
doi:10.1371/journal.pone.0153817.g004
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Fig 5. Persistent metamorphopsia after the resolution of macular edema associated with acute branch retinal vein occlusion. A 74-year-old woman
had visual disturbance due to acute BRVO in the left eye. (A) Fundus photograph. (B) Fluorescein angiogram. (C) The vertical section of an optical
coherence tomography (OCT) scan through the foveal center shows the foveal cystoid spaces and retinal thickening in the affected retina. The visual acuity
of the left eye was 0.30 logMAR. The vertical and horizontal M-CHARTS scores were 1.0 and 0.7, respectively. The eye was treated with an intravitreal
injection of ranibizumab. (D) One month after the injection, a vertical OCT section shows the complete absorption of the macular edema. The visual acuity
was improved to 0.15 logMAR. However, the vertical and horizontal M-CHARTS scores were still both 0.8.
doi:10.1371/journal.pone.0153817.g005
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Discussion
In the current study, metamorphopsia associated with acute BRVO was quantified by
M-CHARTS. Of 42 eyes, metamorphopsia was detected in 29 (69.0%) eyes. The mean vertical
and horizontal scores were 0.59 ± 0.57 and 0.52 ± 0.67, respectively. Kinoshita et al.[20] reported
that an M-CHARTS score of 0.3 to 0.5 may be the threshold for detecting patients with symp-
tomatic metamorphopsia in their daily life. Twenty-five (59.5%) eyes in the current study had
M-CHARTS scores equal to or lager than 0.5 at baseline (data not shown). We can estimate that
approximately 60% of patients with acute BRVO have symptomatic metamorphopsia.
Previous reports showed that the severity of metamorphopsia due to epiretinal membrane is
primarily related to the thickness of the inner nuclear layer [15, 21, 30]. With the use of an
Amsler grid, Watanabe et al.[30] reported that metamorphopsia was detected in the area of
edematous inner nuclear layer in eyes with epiretinal membrane. In our patients with BRVO,
however, the M-CHARTS score had no correlation with the inner retinal thickness. Rather, the
M-CHARTS score was correlated with the height of serous retinal detachment and the maxi-
mum outer retinal thickness. We can speculate that metamorphopsia from acute BRVO is
mainly involved in the morphological changes of the outer retina.
Table 5. Association between Posttreatment M-CHARTS Score and Other Measurement Values at
One Month after Initial Treatment with Ranibizumab.
r p-value
Age 0.20 0.215
Visual acuity (logMAR) 0.28 0.072
Total foveal thickness 0.10 0.389
Thickness of serous retinal detachment -0.14 0.389
Maximum of total retinal thickness -0.07 0.646
Maximum of inner retinal thickness 0.12 0.445
Maximum of outer retinal thickness -0.20 0.212
logMAR, logarithm of the minimum angle of resolution.
Measurement of M-CHARTS was performed at one month after the initial treatment of ranibizumab. The
M-CHARTS score is the higher score of vertical and horizontal scores.
doi:10.1371/journal.pone.0153817.t005
Table 6. Association between Posttreatment M-CHARTS Score and Other Baseline Measurement Val-
ues Associated with Acute Branch Retinal Vein Occlusion.
r p-value
Age 0.20 0.215
Visual acuity (logMAR) 0.29 0.061
Total foveal thickness 0.35 0.024
Thickness of serous retinal detachment 0.20 0.210
Maximum of total retinal thickness 0.16 0.318
Maximum of inner retinal thickness 0.11 0.494
Maximum of outer retinal thickness 0.25 0.114
Baseline M-CHARTS score 0.78 <0.001
logMAR, logarithm of the minimum angle of resolution.
The M-CHARTS score is the higher score of the vertical and horizontal scores.
doi:10.1371/journal.pone.0153817.t006
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One month after treatment with ranibizumab, the mean M-CHARTS score was slightly
decreased. However, most eyes had persistent metamorphopsia in spite of the reduction of ME.
Of 29 eyes that had metamorphopsia at baseline, only three eyes achieved complete resolution.
In an analysis of 5 eyes with BRVO, Achiron et al.[5] reported that there was no improvement in
the M-CHARTS score after the treatments. Similarly, Nakagawa et al.[6] reported that the M-
CHARTS score was unchanged of 6 months in 12 eyes with acute BRVO. Metamorphopsia due
to various diseases has been reported to be decreased as a result of treatment [5, 20, 24, 29]. How-
ever, metamorphopsia from BRVO tends to persist even after complete resolution of the ME.
Of 42 of our patients, 28 had metamorphopsia one month after the treatment. The post-
treatment M-CHARTS score was not associated with any posttreatment factors. However, the
posttreatment M-CHARTS score showed a close correlation with the baseline M-CHARTS
score (r = 0.78, p< 0.001). Once metamorphopsia is induced by morphological changes of the
retina caused by acute BRVO, this symptom often persists, even after the resolution of ME. In
addition, two eyes developed metamorphopsia after the treatment. At baseline, metamorphop-
sia may not have been recognized in these patients due to the severe impairment of visual func-
tion [6].
To date, various pathophysiological mechanisms have been proposed for metamorphopsia
[32–34]. Deformation of the foveal pit or uneven focal retinal thickening or the presence of
cystoid spaces due to BRVOmay cause metamorphopsia [32]. However, based on the limited
improvement of metamorphopsia after the complete resolution of ME, these mechanisms
could not explain metamorphopsia from acute BRVO. In eyes with epiretinal membrane [15,
21, 30], Okamoto et al.[15] speculated that the structural changes of horizontal cells, bipolar
cells, amacrine cells, and Müller cells would inhibit the normal function of synaptic junctions
and lower photoreceptor sensitivity, causing metamorphopsia.
In eyes with BRVO, Yamaike et al.[35] reported a correlation between VA and the integrity
of the outer aspect of the foveal photoreceptor layer. Similarly, metamorphopsia from acute
BRVO may be caused by the morphological changes of the outer aspect of the retina. In addi-
tion, the height of serous retinal detachment was correlated with the M-CHARTS score, and
anteroposterior disorganization of the photoreceptor might be involved in metamorphopsia
form acute BRVO [31]. Recently, adaptive optics-scanning laser ophthalmoscopy showed the
decreased cone density and the disrupted cone mosaic arrangement in the parafoveal area in
eyes with resolved BRVO [36]. Such disarray of the photoreceptors after the absorbance of ME
may account for the persistent metamorphopsia in eyes with BRVO.
One of the major limitations of the current study is the small sample size. In addition, dense
retinal hemorrhage from acute BRVO sometimes made it difficult to analyze the structural
condition of the retina. In the current study, we evaluated the morphological changes of the ret-
ina using OCT, but it would be difficult to evaluate the disarray of each photoreceptor cell
using this technique due to its relatively lower resolution in the retinal plane [37]. In addition,
we aimed to elucidate the pathomorphology that caused the metamorphopsia in eyes with
acute BRVO. We reevaluated the metamorphopsia one month after the treatment because
most eyes showed complete reduction of ME at this time point [38]. We did not identify any
factors that were predictive of the final prognosis of the visual symptoms.
Despite these shortcomings, we were able to quantitatively evaluate the metamorphopsia
associated with acute BRVO using M-CHARTS. Even after the reduction of ME with anti-vas-
cular endothelial growth factor agents, some patients still suffer from decreased quality of
vision due to symptomatic metamorphopsia. Further prospective studies with longer follow-up
periods are necessary to elucidate the long-term changes of metamorphopsia associated with
BRVO.
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